Hypoglycemia: Minimizing its impact in type 2 diabetes

Endocrine Practice

Volumn 19, Issue 3, 2013, Pages 526-535

  Moghissi, Etie ^a   Ismail Beigi, Faramarz ^b   Devine, Robin Cammarota ^c  

^a University of California   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BILE ACID SEQUESTRANT; CORTICOTROPIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

BLADDER CANCER; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; EMERGENCY WARD; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 84880086034     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13005.RA     Document Type: Review

References (55)

1. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med. 2012;29:293-302.
2. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis o. The ACCORD study. BMJ. 2010;340:b4909.
3. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33: 1389-1394.
4. Fidler C, Elmelund Christensen T, Gillard S. Hypo-glycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14: 646-655.
5. Garber AJ. Hypoglycaemia: a therapeutic concern in type 2 diabetes. Lancet. 2012;379:2215-2216.
6. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings fro. The Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10(Suppl 1):25-32.
7. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007;21:220-226.
8. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011; 17(Suppl 2):1-53.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of gyperglycemia in type 2 diabetes: a patient-centered approach: position statement o. The American Diabetes Association (ADA) an. The European Association fo. The Study of Diabetes (EASD). Diabetes Care. 2012;35: 1364-1379.
10. Rodbard H, Jellinger P, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endrocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
11. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
13. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.
14. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-559.
15. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57:3169-3176.
16. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948-2961.
17. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives an. The risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997; 278:40-43.
18. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus. The results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5:19-26.
19. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-1147.
20. Liu S, Zhao Y, Hempe JM, Fonseca V, Shi L. Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res. 2012;12:47-51.
21. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26: 1485-1489.
22. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405-414.
23. Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356:1842-1852.
24. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301:1565-1572.
25. Aung PP, Strachan MW, Frier BM, et al. Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes. The Edinburgh Type 2 Diabetes Study. Diabet Med. 2012;29:328-336.
26. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012.
27. Green AJ, Fox KM, Grandy S, SHIELD Study Group. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313-318.
28. American Diabetes Association, Lorber D, Anderson J, et al. Diabetes and driving. Diabetes Care. 2012;35(Suppl 1):S81-S86.
29. Ginde AA, Espinola JA, Camargo CA Jr. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005. Diabetes Care. 2008;31:511-513.
30. Jansen J. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22:671-681.
31. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
32. Bonds DE, Miller ME, Dudl J, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis o. The ACCORD clinical trial data. BMC Endocr Disord. 2012;12:5.
33. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
34. Klonoff D, Bergenstal R, Blonde L, et al. Consensus report o. The coalition for clinical research-self-monitoring of blood glucose. Diabetes Sci Technol. 2008;2:1030-1053.
35. Reinberg S. FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves. Available at: http://health.usnews.com/health-news/diet-fitness/diabetes/ articles/2011/05/19/fda-to-pull-diabetes-drug-avandia-from-pharmacy-shelves. Accessed February 7, 2013.
36. Campbell RK. Clarifyin. The role of incretin-based therapies i. The treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:511-527.
37. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-613.
38. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50:865-879.
39. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A Real-World Approach to Insulin Therapy in Primary Care Practice. Clinical Diabetes. 2005;23:78-86.
40. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281: 2005-2012.
41. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes-focus on insulin. Diabetes Metab Res Rev. 2005;21: 85-90.
42. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achievin. The hemoglobin A1c target of
43. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
44. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498-1507.
45. American Diabetes Association. Practical Insulin: A Handbook for Prescribing Providers. 3rd ed. Alexandria, VA: American Diabetes Association, 2011.
46. Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab. 2011;13:1142-1148.
47. Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. Diabetes. 2011;60(Suppl 1):LB14.
48. Ratner RE, Gough S, Mathieu C, et al. Hypoglycemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a prospective meta-analysis of phase 3 trials. Diabetes Obese Metab. 2013;15:175-184.
49. Kiss I, Arold G, Bettcher SG, Thrane M, Haarh HI. Insulin Degludec has Similar Pharmacokinetic Properties in Subjects with Renal Impairment and Subjects with Normal Renal Function. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA: 2012: 1151-P.
50. Vilsboll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167-177.
51. Barnett A. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia. 2011;54(Suppl 1): S108-S109.
52. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103-112.
53. Bain S. Adding Insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycemia rate: 52-week results. Diabetologia. 2011;54(Suppl 1):73.
54. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. New Engl J Med. 2009;361:1736-1747.
55. Wariaghli G, Mounach A, Achemlal L, et al. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int. 2010;30:893-899.